Broadly Protective Protein-Based Pneumococcal Vaccine Composed of Pneumolysin Toxoid-CbpA Peptide Recombinant Fusion Protein
Pneumococcus, meningococcus and Haemophilus influenzae cause a similar spectrum of infections in the ear, lung, blood, and brain. They share cross-reactive antigens that bind to the laminin receptor of the blood-brain barrier as a molecular basis for neurotropism, and this step in pathogenesis was addressed in vaccine design. This article, published in the Journal of Infectious Diseases, reports results from a study where biologically active peptides derived from choline-binding protein A (CbpA) of pneumococcus were identified and then genetically fused to L460D pneumolysoid. The fusion construct was tested for vaccine efficacy in mouse models and results showed that the CbpA peptide-L460D pneumolysoid fusion was more broadly immunogenic than pneumolysoid alone and antibodies were active in vitro against all three bacteria. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Mann B, Thornton J, Heath R, et al.
Visit web page (English)
(Located at jid.oxfordjournals.org)
Citation: Mann B, Thornton J, Heath R, et al. Broadly Protective Protein-Based Pneumococcal Vaccine Composed of Pneumolysin Toxoid-CbpA Peptide Recombinant Fusion Protein. Journal of Infectious Diseases. 2013; Early Online Publication.